Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy
Abstract
Androgen deprivation therapy (ADT) has been the standard of care for advanced hormone‐sensitive prostate cancer (PC), yet tumors invariably develop resistance resulting in castrate‐resistant PC. The acute response of cancer cells to ADT includes apoptosis and cell death, but a large fraction remains arrested but viable. In this study, we focused on intensively characterizing the early metabolic changes that result after ADT to define potential metabolic targets for treatment.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 18, 2022
- Source ID
- 10.1002/pros.24428
Entities
People
- Amani A. Gillette
- Bing Yang
- David F Jarrard
- Melissa C. Skala
- Mikolaj J. Filon
- Tariq A. Khemees
Organizations
- American Urological Association
- Morgridge Institute for Research
- National Institutes of Health Clinical Center
- United States Department of Defense
- University of Wisconsin Hospital and Clinics
- University of Wisconsin–Madison